Skip to main content
CERT logo

CERT · Certara, Inc.

Track CERT — free
$11.21 -0.37 (-3.15%)
Market Cap
$1.76B
Shares
152.54M
Volume · Nov 16 472.07K Avg daily vol (3M) 2.62M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.57 Open$12.02 Day$11.55–12.18 52W close$4.48–12.22 Avg vol 30d2.8M Short int25.5M · 16.7% of shares · 11.6d Short vol51% Last earningsNov 5, 2026 DataDec 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 5
Earnings call
Software growth accelerates as 2026 outlook tightens

Certara posted third-quarter revenue of $94.9 million, up 4% year over year, as software revenue grew 11% to $48.8 million while services revenue fell 2% to $46.1 million. It narrowed 2026 revenue growth guidance to 2-3%.

4 source passages
Total revenue for the three months ended September 30, 2026, was $94.9 million, an increase of 4% year over year. Software revenue was $48.8 million in the third quarter, an increase of 11% year-over-year, driven by strong retention and continued growth across our major portfolios. Services revenue was $46.1 million in the third quarter, a decrease of 2% year-over-year. We are narrowing our 2026 full-year revenue growth range to 2-3%. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 4% as quarterly net loss narrows

Certara reported third-quarter revenue growth of 4% and a net loss of $3.6 million, versus $4.8 million a year earlier. It completed the sale of its Regulatory and Medical Writing business on May 8, 2026, receiving $78.2 million by September 30, 2026.

Revenue $94.9M ▲ 4.4% Net income $5.59M ▲ 266.7% Diluted EPS $0.04 ▲ 300.0%
Read from the MD&A section
3 source passages
Total revenues increased by $4.0 million, or 4%, to $94.9 million for the three months ended September 30, 2026 as compared to the same period in 2025. Net loss was $3.6 million, representing a $1.3 million increase in net income for the three months ended September 30, 2026 as compared to net loss of $4.8 million for the same period of 2025. On May 8, 2026, the Company completed the sale of the Regulatory and Medical Writing business. As of September 30, 2026, the Company had received cash consideration of $78.2 million. Open the document at this passage
Nov 5
Current report 8-K
Software revenue grows 11%, outlook narrows

Certara reported third-quarter revenue of $94.9 million, up 4%, and software revenue of $48.8 million, up 11%. It narrowed 2026 revenue growth guidance to 2% to 3% and adjusted diluted EPS guidance to $0.31 to $0.34.

Financial results
4 source passages
Revenue was $94.9 million, compared to $90.9 million in the third quarter of 2025, representing growth of 4%. Software revenue was $48.8 million, compared to $43.8 million in the third quarter of 2025, representing growth of 11%. Revenue: The Company is narrowing its 2026 full year revenue growth range to 2% to 3%. Adjusted Diluted Earnings Per Share: The Company is updating its expected full-year adjusted diluted earnings per share range to $0.31 to $0.34. Open the document at this passage
Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $93.27M ▲ 1.0% Net loss $55.27M Diluted EPS -$0.36
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$424.68M
Trailing 12 months
Net income (TTM)
−$64.34M
Trailing 12 months
Revenue growth YoY
+4.4%
Year over year
Operating margin
1.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$76.28M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-4.8%
Year over year · fewer shares
Price change (1Y)
+37.6%
Trailing year
Short interest
16.7%
Latest settlement · 11.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Revenue grew 4%, software revenue grew 11%, software bookings grew 15%, and adjusted EBITDA margin improved to 31.8%; Certara also generated $30.7 million of operating cash and ended with $214.9 million in cash. Services revenue and bookings declined, adjusted net income decreased, GAAP losses persisted, operating expenses rose, and Phoenix Cloud conversions create a revenue headwind.

Bullish
  • + Adjusted EBITDA rose 6% and margin improved to 31.8% from 28.1% in the second quarter. new
  • + Grant Peterson was appointed Chief Product Officer to accelerate growth across existing and new products. new
  • + Certara won new FDA contracts and received a three-year SIMSIT research contract. new
  • + Certara generated $30.7 million of cash from continuing operations and ended with $214.9 million in cash. new
Bearish
  • − Operating expenses increased $3.1 million, primarily due to reorganization, severance, and executive recruiting costs. new
  • − Certara remained unprofitable on a GAAP basis, reporting a $3.6 million loss from continuing operations. new
  • − Phoenix Cloud conversions create a revenue headwind. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +57%
above
Price vs 50-day avg +19%
above
RSI (14) 60
neutral
MACD trend Negative
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +23%
trailing
6-month return +122%
trailing
YTD return +31%
this year
Relative strength +122%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow Distributing
223 of 244 funds reported for Sep 30 · net -6.4M sh shares · +36 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.74% of shares out · ▼ -0.6% MoM · 11.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
244 holders — mid 3-yr range
Squeeze score 79
high risk · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
EPS growth +88%
Y/Y
Free cash flow $94.6M
Buyback $50.0K
authorized
Balance sheet $103.7M
net debt
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −56%
past year
ATR 5.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 3
Latest guidance · from the 8-K filed Nov 5, 2026
full-year 2026
Adjusted Diluted Earnings Per Share Non-GAAP Lowered $0.31 – $0.34
May 11, 2026 $0.35 – $0.41 changed to Nov 5, 2026 $0.31 – $0.34
Effective Tax Rate Lowered 25% – 30%
May 11, 2026 30% changed to Nov 5, 2026 25% – 30%
fourth quarter
Adjusted EBITDA margin Non-GAAP 29% – 31%
Previous outlook earlier release · from the 8-K filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Run-rate savings · $13M
Guided vs delivered · last 3 settled
Revenue 2025
guided $415M – $420M
$418.84M In line
Full year 2024 revenue full year 2024
guided $385M – $400M
$385.15M In line
Revenue FY 2021 (including Pinnacle 21)
guided $288M – $291M
$286.1M Miss −1.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+57% Bullish
Price vs 50-day avg
+19% Bullish
RSI (14)
60 Neutral
MACD trend
Negative Bearish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $10 › 200d $7 — 50d above 200d
Institutional flow Distributing
223 of 244 funds reported for Sep 30 · net -6.4M sh shares · +36 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
16.74% of shares out · ▼ -0.6% MoM · 11.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
244 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4 Now $12 · 92% Range high $12
vs 200-day avg +57% vs 50-day avg +19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted diluted earnings per share non-GAAP $0.14 six months ended June 30, 2026 —
Adjusted EBITDA non-GAAP 52.88M six months ended June 30, 2026 —
Adjusted net income non-GAAP 21.57M six months ended June 30, 2026 —
Average price per share repurchased under stock repurchase program $5.46 the three months ended June 30, 2026 filing —
Services Bookings $47.6M the second quarter of 2026 —
Share repurchase program repurchased in the second quarter $17.4M the second quarter —
shares of its common stock repurchased 3,194,975 the three months ended June 30, 2026 filing —
Shares tendered by employees for tax payments on RSU vesting 585,391 the three months ended June 30, 2026 filing —
Software Bookings $50.7M the second quarter of 2026 —
Total Number of Shares Purchased 3,780,366 the three months ended June 30, 2026 filing —
Year-to-date discontinued operations Revenue $19.2M year-to-date through the transaction closing on May 8, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CERT
Certara, Inc.
this stock
$1.76B +31.3% +8.7% — 16.7%
VEEV
Veeva Systems Inc
$48.82B +35.1% +28.1% 49.4 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$14.17B +90.1% +28.2% 38.7 5.8%
TEM
Tempus AI, Inc.
$13.06B +21.3% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
252
% held
84.0%
Reported
223 of 244
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
243
View
Short & Settlement
Short Interest Falling
Shares short
25.5M
Days to cover
11.6d
Change
-151.8K sh
View
Short Volume
Short vol %
51%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
430
Value
$4.8K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
36.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$418.8M
Net income (FY)
$-1.6M
EPS diluted
$-0.01
View
Buybacks
Authorized
$50.0K
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
19

Certara reported third-quarter revenue growth of 4% and a net loss of $3.6 million, versus $4.8 million a year earlier. It completed the sale of its Regulatory and Medical Writing business on May 8, 2026, receiving $78.2 million by September 30, 2026.

View
Proposed Sales
Value
$300.1K
Shares
36.1K
Filed
Sep 3, 2026
View
Exempt Offerings
Offering
Indefinite
Filed
Apr 28, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Certara Reports Third Quarter 202…
Published
Nov 5, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
CERT -4.0% +23.5% +122.1% +5.0% +31.3%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -6.6% +24.6% +121.6% +5.2% +20.7%

Capital returns

Buyback program · as of Aug 3, 2026
Authorized
$50,000
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1827090 CUSIP 15687V109 13F (30d) 204 filings 182 filers Visit website Investor relations